Artwork

Content provided by Ben Gilbert and David Rosenthal, Ben Gilbert, and David Rosenthal. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Ben Gilbert and David Rosenthal, Ben Gilbert, and David Rosenthal or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Novo Nordisk (Ozempic)

3:44:55
 
Share
 

Manage episode 396789583 series 2483609
Content provided by Ben Gilbert and David Rosenthal, Ben Gilbert, and David Rosenthal. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Ben Gilbert and David Rosenthal, Ben Gilbert, and David Rosenthal or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Last year Novo Nordisk, the Danish pharmaceutical company behind Ozempic and Wegovy, overtook LVMH to become Europe’s most valuable company. And the pull for Acquired to finally tackle healthcare (18% of US GDP!) became too strong for us to resist. While we didn’t know much about Novo Nordisk before diving in, our first thought was, “wow, seems like these new diabetes and obesity drugs mean serious trouble for big insulin companies.”

And then… we realized that Novo Nordisk IS the big insulin company. And in a story befitting of Steve Jobs and Apple, they’d just disrupted themselves with the drug equivalent of an iPhone moment. Once we dug further, we quickly realized this company has it all: an incredible 100+ year history filled with Nobel Prizes, bitter personal rivalries, board room dramas, a generation-defining silicon valley innovation, lone voices persevering against all odds — and oh yeah, the world’s largest charitable foundation at its helm. Tune in for one incredible story!

Sponsors:

Many thanks to our fantastic Season 14 partners:

More Acquired:

Links:

Carve Outs:

‍Note: Acquired hosts and guests may hold assets discussed in this episode. This podcast is not investment advice, and is intended for informational and entertainment purposes only. You should do your own research and make your own independent decisions when considering any financial transactions.

  continue reading

225 episodes

Artwork

Novo Nordisk (Ozempic)

Acquired

2,149 subscribers

published

iconShare
 
Manage episode 396789583 series 2483609
Content provided by Ben Gilbert and David Rosenthal, Ben Gilbert, and David Rosenthal. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Ben Gilbert and David Rosenthal, Ben Gilbert, and David Rosenthal or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Last year Novo Nordisk, the Danish pharmaceutical company behind Ozempic and Wegovy, overtook LVMH to become Europe’s most valuable company. And the pull for Acquired to finally tackle healthcare (18% of US GDP!) became too strong for us to resist. While we didn’t know much about Novo Nordisk before diving in, our first thought was, “wow, seems like these new diabetes and obesity drugs mean serious trouble for big insulin companies.”

And then… we realized that Novo Nordisk IS the big insulin company. And in a story befitting of Steve Jobs and Apple, they’d just disrupted themselves with the drug equivalent of an iPhone moment. Once we dug further, we quickly realized this company has it all: an incredible 100+ year history filled with Nobel Prizes, bitter personal rivalries, board room dramas, a generation-defining silicon valley innovation, lone voices persevering against all odds — and oh yeah, the world’s largest charitable foundation at its helm. Tune in for one incredible story!

Sponsors:

Many thanks to our fantastic Season 14 partners:

More Acquired:

Links:

Carve Outs:

‍Note: Acquired hosts and guests may hold assets discussed in this episode. This podcast is not investment advice, and is intended for informational and entertainment purposes only. You should do your own research and make your own independent decisions when considering any financial transactions.

  continue reading

225 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide